Wechselwirkungen · Rydapt
Rydapt 25 mg soft capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-135073 · Präparat HOS-097652
Strong CYP3A4 inducers Concomitant use of Rydapt with strong inducers of CYP3A4 (e.g. carbamazepine, rifampicin, enzalutamide, phenytoin, St. John’s Wort [Hypericum perforatum]) is contraindicated (see section 4.3). Strong CYP3A4 inducers decrease exposure of midostaurin and its active metabolites (CGP52421 and CGP62221). In a study in healthy subjects, co-administration of the strong CYP3A4 inducer rifampicin (600 mg daily) to steady state with a 50 mg single dose of midostaurin decreased midostaurin Cmax by 73% and AUCinf by 96% on average, respectively. CGP62221 exhibited a similar pattern. The mean AUClast of CGP52421 decreased by 60%.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) phenytoin (HOS-084531) enzalutamide (HOS-116829)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-14T02:00:00Z · SHA-256 8f1ec9efb6021159ac982022053e37b35f5bff1afb750b66862153d8db724917 · Passage d2e766553fc20543bb141525643189ea4fe9570d38e8d88cfa437287f11b558e · Zeichen 390–1037 im Abschnitt